Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.14)
# 1,137
Out of 4,868 analysts
103
Total ratings
46.67%
Success rate
1.66%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $90.92 | +9.99% | 1 | Jun 11, 2025 | |
| UTHR United Therapeutics | Initiates: Overweight | $405 | $291.72 | +38.83% | 1 | Jun 2, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.53 | +186.98% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $55.24 | +62.93% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $448.40 | +7.05% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $46.84 | +17.42% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $108.00 | -25.93% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.22 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $513.58 | +97.63% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $289.63 | +39.83% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $312.32 | -29.56% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $7.92 | +26.26% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.81 | +70.60% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $44.43 | +62.05% | 1 | Apr 13, 2023 |
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $90.92
Upside: +9.99%
United Therapeutics
Jun 2, 2025
Initiates: Overweight
Price Target: $405
Current: $291.72
Upside: +38.83%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.53
Upside: +186.98%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $55.24
Upside: +62.93%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $448.40
Upside: +7.05%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $46.84
Upside: +17.42%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $108.00
Upside: -25.93%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.22
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $513.58
Upside: +97.63%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $289.63
Upside: +39.83%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $312.32
Upside: -29.56%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.92
Upside: +26.26%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.81
Upside: +70.60%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $44.43
Upside: +62.05%